drugset / Trial / NCT02387762

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

NCT02387762

Phase 2 Completed 31 enrolled Acerta Pharma BV
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.

Timeline

Start
2015-04
Primary completion
2016-05
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 15 mg Oral

Indications